LyGenesis will soon begin a clinical trial for patients with end-stage liver disease who are not able to receive a transplant. The intervention is a simple out-patient procedure that injects liver cells into one or more lymph nodes, which serve as bioreactors to grow one or more new, functional mini-organs. The procedure has worked in mice, dogs, and pigs. LyGenesis uses cells from discarded organs not used for transplant, and a single organ can provide cells for potentially dozens of patients. The whole clinical trial is likely to take about two years.

As with traditional organ transplants, patients will need to take immunosuppressants to not reject the donor cells. However, LyGenesis has partnered with iTolerance to find ways to transplant cells and tissue without lifelong need for immunosuppressants.

LyGenesis's pipeline also includes the thymus, pancreas, and kidneys.